The Corvus Cabal worships the Great Gatherer by taking treasures from the victims of their ambushes and assassinations. They believe the Archaon is an avatar of their god and as such, seek to gain his ...

The free-agent landscape shifts with every significant move. The New York Yankees have been very agile in adapting to those shifts this winter and the latest one may give them another opportunity.

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) just reported positive results from its phase 1 study using soquelitinib [CPI-818] for the treatment of patients with atopic dermatitis [AD]. Being that ...

Corvus Pharmaceuticals (NASDAQ:CRVS) lost ~34% in the premarket on Wednesday after the company announced early results from a Phase 1 trial for its lead asset, soquelitinib, in patients with ...

Soquelitinib reduced EASI scores by 55.9% at 28 days and 69.1% at 58 days versus 27.0% and 19.1% for placebo. At day 58, 90% of soquelitinib patients achieved EASI 50, with no significant safety ...

A multimillionaire transgender women who has changed gender three times is suing the NHS after having a 'botched' realignment operation which left her in 'constant pain'. Self-styled 'lady of ...

BOCA CHICA, Texas – To Gilberto Salinas, the gleaming glass-and-steel building with the “SPACEX” sign emblazoned across its top stretching along State Highway 4 represents a portal into the ...

Dec. 18, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced interim data from the randomized, double-blind ...

Regulators have revoked the licence of an Ontario dentist after Global News revealed he was practicing under a name he adopted following his conviction for helping Iran evade sanctions. Dr.

BURLINGAME, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced interim ...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) released interim data from a Phase 1 trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. The trial will enroll 64 ...

Today, a brief rundown of news involving Tessera Therapeutics and Corvus Pharmaceuticals, as well as updates from Sarepta Therapeutics, Cara Therapeutics and Johnson & Johnson that you may have missed ...